SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Solventum Corporation (SOLV) trades at a trailing P/E of 7.2, forward P/E of 10.7. Trailing earnings yield is 13.93%, forward earnings yield 9.38%. PEG 0.03 (Peter Lynch undervalued ≤1.0). Graham Number is $76.37.
Criteria proven by this page:
- VALUE (76/100, Pass) — P/E is below market average (7.2); PEG ≤ 1.0 — Peter Lynch undervalued (0.03); analyst target implies upside (+45.6%); earnings yield beats bond yields (13.93%).
- PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 13.93% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
- Analyst consensus target $100.50 (+45.6% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 73/100 with 6/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
76/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SOLV
Valuation Multiples
P/E (TTM)7.2
Forward P/E10.7
PEG Ratio0.03
Forward PEG1.67
P/B Ratio2.21
P/S Ratio1.34
EV/EBITDA5.4
Per Share Data
EPS (TTM)$8.94
Forward EPS (Est.)$6.48
Book Value / Share$29.00
Revenue / Share$47.82
FCF / Share$-0.06
Yields & Fair Value
Earnings Yield13.93%
Forward Earnings Yield9.38%
Dividend Yield0.00%
Graham Number$76.37
SharesGrow IV$6.98 (-89.9%)
Analyst Target$100.50 (+45.6%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2020 |
12.1 |
0.00 |
0.00 |
1.89 |
- |
| 2021 |
9.5 |
0.33 |
1.14 |
1.69 |
- |
| 2022 |
10.3 |
-1.28 |
1.18 |
1.70 |
- |
| 2023 |
10.3 |
235.19 |
1.18 |
1.69 |
- |
| 2024 |
23.9 |
-0.37 |
3.87 |
1.39 |
- |
| 2025 |
8.9 |
0.04 |
2.73 |
1.66 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$6.60 |
$7.28B |
$1.14B |
15.6% |
| 2021 |
$8.47 |
$8.17B |
$1.46B |
17.9% |
| 2022 |
$7.79 |
$8.13B |
$1.34B |
16.5% |
| 2023 |
$7.79 |
$8.2B |
$1.35B |
16.4% |
| 2024 |
$2.76 |
$8.25B |
$479M |
5.8% |
| 2025 |
$8.88 |
$8.33B |
$1.56B |
18.7% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$6.47 |
$6.23 – $6.53 |
$8.16B |
$7.74B – $8.36B |
8 |
| 2027 |
$7.02 |
$6.90 – $7.22 |
$8.45B |
$8.04B – $8.59B |
7 |
| 2028 |
$7.72 |
$3.62 – $10.70 |
$8.79B |
$8.77B – $8.82B |
3 |
| 2029 |
$7.81 |
$7.27 – $8.00 |
$8.95B |
$8.47B – $9.12B |
1 |
